Personalizing Medicine through AI

Our Approach

October Is Breast Cancer Awareness Month

On average, every two minutes a woman is diagnosed with breast cancer in the United States.

About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.

PreciseDx is dedicated to supporting more personalized and precise treatments for breast cancer.

Learn More

About PreciseDx

PreciseDx is an augmented intelligence healthcare services provider delivering patient-specific insights that aid in disease state characterization and enable better treatment decisions and outcomes. Our pipeline addresses high-impact areas such as breast cancer.

Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists

Better Data. Better Outcomes.

PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.

  • Patients
  • Providers
  • Payers
  • BioPharma

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Patients

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

Providers

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

Payers

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

BioPharma

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

“PreciseDx has an opportunity to improve the quality for all patients through our digital platform. The level of patient-specific detail we can provide to oncologists and pathologists is unmatched, and our ability to provide this as a digital service means that we are not bound by location.”

Jack Zeineh, PreciseDx

“PreciseDx has an opportunity to improve the quality for all patients through our digital platform. The level of patient-specific detail we can provide to oncologists and pathologists is unmatched, and our ability to provide this as a digital service means that we are not bound by location.”

Featured Resources & Media

Publication
September 3, 2021
An AI-Digital Breast Cancer Risk Discrimination Platform Accurately Categorized Patients with Oncotype Dx Low Risk Recurrence Scores
News Article
December 10, 2020
PreciseDx Accurately Classifies Low-Risk Recurrence Scores in Breast Cancer
Poster
December 8, 2020
San Antonio Breast Cancer Symposium

Interested in Learning More?

Contact Us